Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.64 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.63 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.51 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10349749 | 0.94 | PARP10 (0.71) | NPC1RAB9APARP10FFAR1AKR1B1 | |
| SCHEMBL2516394 | 0.87 | PARP10 (0.68) | NPC1RAB9APARP10FFAR1AKR1B1 | |
| SCHEMBL15249121 | 0.85 | PARP10 (0.61) | NPC1RAB9APARP10FFAR1AKR1B1 | |
| SCHEMBL4050754 | 0.85 | PARP10 (0.57) | NPC1RAB9APARP10FFAR1AKR1B1 | |
| SCHEMBL5709923 | 0.85 | NPC1 (0.53) | NPC1RAB9APARP10FFAR1AKR1B1 | |
| SCHEMBL15249123 | 0.84 | NPC1 (0.64) | NPC1RAB9APARP10FFAR1AKR1B1 | |
| SCHEMBL20024703 | 0.84 | NPC1 (0.61) | NPC1RAB9APARP10FFAR1AKR1B1 | |
| SCHEMBL4058335 | 0.84 | PARP10 (0.76) | NPC1RAB9APARP10FFAR1AKR1B1 | |
| SCHEMBL15249111 | 0.83 | NPC1 (0.63) | NPC1RAB9APARP10FFAR1AKR1B1 | |
| SCHEMBL123733 | 0.83 | FFAR1 (0.62) | NPC1RAB9APARP10FFAR1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106632507-B | Metal complex and preparation method thereof, and preparation method of olefin binary copolymer | 中国石油天然气股份有限公司 | 2019-03-12 | — | — | CN | disclosed |
| CN-108077265-A | A kind of difenolan derivative pesticide composition and its application in pest control | 上海生农生化制品股份有限公司 | 2018-05-29 | — | — | CN | disclosed |
| US-20150130318-A1 | RESIN COMPOSITION FOR ROTOR FIXING, ROTOR, AND AUTOMOTIVE VEHICLE | SUMITOMO BAKELITE CO., LTD. (JP) | 2015-05-14 | — | — | US | disclosed |
| US-20150130318-A1 | RESIN COMPOSITION FOR ROTOR FIXING, ROTOR, AND AUTOMOTIVE VEHICLE | SUMITOMO BAKELITE CO., LTD. (JP) | 2015-05-14 | — | — | US | disclosed |
| EP-2821437-A1 | RESIN COMPOSITION FOR ROTOR FIXING, ROTOR, AND AUTOMOTIVE VEHICLE | Sumitomo Bakelite Company Limited (JP) | 2015-01-07 | — | — | EP | disclosed |
| US-20140356430-A1 | PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO [2,3-B]PYRAZIN-2(1H)-ONE, A SOLID FORM THEREOF AND METHODS OF THEIR USE | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-12-04 | — | — | US | disclosed |
| US-20130237639-A1 | CURABLE RESIN COMPOSITION, CURED PRODUCT THEREOF, PHENOLIC RESIN, EPOXY RESIN, AND SEMICONDUCTOR SEALING MATERIAL | DIC CORPORATION (JP) | 2013-09-12 | — | — | US | disclosed |
| US-20130237639-A1 | CURABLE RESIN COMPOSITION, CURED PRODUCT THEREOF, PHENOLIC RESIN, EPOXY RESIN, AND SEMICONDUCTOR SEALING MATERIAL | DIC CORPORATION (JP) | 2013-09-12 | — | — | US | disclosed |
| US-7199139-B2 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-1354602-B1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | SANKYO CO (JP) | 2006-10-04 | — | — | EP | disclosed |
| US-5703096-A | ANTIDIABETIC AGENTS; ALDOSE REDUCTASE INHIBITOR | SANKYO COMPANY, LIMITED (JP) | 1997-12-30 | — | — | US | disclosed |
| EP-0708098-A1 | Oxime derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |
| EP-0172427-B1 | PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER | Shin-Etsu Chemical Co., Ltd. (JP) | 1989-07-05 | — | — | EP | disclosed |
| US-4758639-A | Process for production of vinyl polymer | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-19 | — | — | US | disclosed |
| US-4757124-A | Suspension or emulsion polymerizing vinyl chloride monomer or mixture of vinyl chloride with vinyl monomer copolymerizable therewith in reactor with walls coated with antiscaling compound containing dye or pigments | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-12 | — | — | US | disclosed |
| US-4728668-A | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments | USV PHARMACEUTICAL CORPORATION (US) | 1988-03-01 | — | — | US | disclosed |
| US-4725619-A | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments | USV PHARMACEUTICAL CORPORATION (US) | 1988-02-16 | — | — | US | disclosed |
| US-4631287-A | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments | USV PHARMACEUTICAL CORP. (US) | 1986-12-23 | — | — | US | disclosed |
| EP-0200101-A2 | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive aliments | USV PHARMACEUTICAL CORPORATION (US) | 1986-11-05 | — | — | EP | disclosed |
| EP-0172427-A2 | Process for production of vinyl chloride polymer | Shin-Etsu Chemical Co., Ltd. (JP) | 1986-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140356430-A1 | PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO [2,3-B]PYRAZIN-2(1H)-ONE, A SOLID FORM THEREOF AND METHODS OF THEIR USE | CYP11B2, CYP27A1, CYP11B1 | NPC1 167/4885RAB9A 2666/4885PARP10 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.